Prevalence of Serum Anti-insulin Antibodies and Clinical Features in Patients With Type 2 Diabetes Treated With Insulin Analogues

DOI
  • Tamagawa Eri
    Department of Diabetic Medicine, Hannan Municipal Hospital, Seichokai Social Medical Corporation
  • Matsuoka Yuko
    Clinical Center for Diabetes, Fuchu Hospital, Seichokai Social Medical Corporation
  • Kadoya Yoshiki
    Clinical Center for Diabetes, Fuchu Hospital, Seichokai Social Medical Corporation
  • Yamada Shoichi
    Clinical Center for Diabetes, Fuchu Hospital, Seichokai Social Medical Corporation
  • Fujita Atsuyo
    Department of Diabetic Medicine, Hannan Municipal Hospital, Seichokai Social Medical Corporation
  • Sanke Tokio
    Institute for Diabetes, Fuchu Hospital, Seichokai Social Medical Corporation

Bibliographic Information

Other Title
  • インスリンアナログ製剤により治療されている2型糖尿病患者の血中抗インスリン抗体の陽性頻度と臨床像

Search this article

Abstract

<p>Recently, insulin analogues have come to be widely used in Japan. We therefore examined the prevalence of serum anti-insulin antibodies in type 2 diabetic patients treated with human insulin or other insulin analogues and compared the clinical features of those with and without antibodies. Fasting serum from type 2 diabetic patients treated with identical insulin preparations for the first time in more than 1 year (Human [N=22], Aspart [N=31], Rispro [N=23], and Glargine [N=23]) were used. Anti-insulin antibodies were measured by a radioimmunoassay using I125-labeled human insulin. Rates of positive test results for antibodies were 0 % in Human, 58.1 % in Aspart, 39.1 % in Lispro, and 34.8 % in Glargine. In patients treated with analogues, the daily treating insulin dose was significantly higher (p=0.009) in those with antibodies than in those without antibodies, as demonstrated by an analysis of covariance adjusted for the body mass index, HbA1c, period of insulin treatment and presence of combined anti-diabetic drugs. The incremental dose amounted to 34.3 % of that in those without antibodies. Anti-human insulin antibodies were developed in patients treated with insulin analogues at a considerably high rate. In these patients, a higher dose of daily insulin treatment was needed than in those without antibodies.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top